A Dynamic Prognostic Model for Identifying Vulnerable COVID ‐19 Patients at High Risk of Rapid Deterioration
Pharmacoepidemiology and Drug Safety · 2024
DOI: 10.1002/pds.5872 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Priyanka Anand und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass…. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institution of Health, NIA NIH HHS, NLM NIH HHS.
Abstract (Originalsprache)
Purpose
We aimed to validate and, if performance was unsatisfactory, update the previously published prognostic model to predict clinical deterioration in patients hospitalized for COVID‐19, using data following vaccine availability.
Methods
Using electronic health records of patients ≥18 years, with laboratory‐confirmed COVID‐19, from a large care‐delivery network in Massachusetts, USA, from March 2020 to November 2021, we tested the performance of the previously developed prediction model and updated the prediction model by incorporating data after availability of COVID‐19 vaccines. We randomly divided data into development (70%) and validation (30%) cohorts. We built a model predicting worsening in a published severity scale in 24 h by LASSO regression and evaluated performance by c‐statistic and Brier score.
Results
Our study cohort consisted of 8185 patients (Development: 5730 patients [mean age: 62; 44% female] and Validation: 2455 patients [mean age: 62; 45% female]). The previously published model had suboptimal performance using data after November 2020 ( N = 4973, c‐statistic = 0.60. Brier score = 0.11). After retraining with the new data, the updated model included 38 predictors including 18 changing biomarkers. Patients hospitalized after Jun 1st, 2021 (when COVID‐19 vaccines became widely available in Massachusetts) were younger and had fewer comorbidities than those hospitalized before. The c‐statistic and Brier score were 0.77 and 0.13 in the development cohort, and 0.73 and 0.14 in the validation cohort.
Conclusion
The characteristics of patients hospitalized for COVID‐19 differed substantially over time. We developed a new dynamic model for rapid progression with satisfactory performance in the validation set.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Priyanka Anand, Shirley V Wang
Förderung
- National Institution of Health
- NIA NIH HHS
- NLM NIH HHS
Zitieren
APA
Anand, P., D'Andrea, E., Feldman, W., Wang, S. V., Liu, J., Brill, G., DiCesare, E., & Lin, K. J. (2024). A Dynamic Prognostic Model for Identifying Vulnerable COVID ‐19 Patients at High Risk of Rapid Deterioration. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5872
Vancouver
Anand P, D'Andrea E, Feldman W, Wang SV, Liu J, Brill G, et al. A Dynamic Prognostic Model for Identifying Vulnerable COVID ‐19 Patients at High Risk of Rapid Deterioration. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5872
BibTeX
@article{Anand2024,
author = {Anand, Priyanka and D'Andrea, Elvira and Feldman, William and Wang, Shirley V and Liu, Jun and Brill, Gregory and DiCesare, Elyse and Lin, Kueiyu Joshua},
title = {A Dynamic Prognostic Model for Identifying Vulnerable COVID ‐19 Patients at High Risk of Rapid Deterioration},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
doi = {10.1002/pds.5872}
}
EUVIMED